NCT05210413 2026-01-15
SPARTO
University Hospital, Bordeaux
Phase 1/2 Active not recruiting
Clinical Trials
15 trialsNCT06895733 2025-03-26
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)
Tianjin Medical University Second Hospital
Phase 1/2 Recruiting
NCT06739395 2024-12-18
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT01430572 2023-06-06
Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01407562 2022-09-28
Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors
Rutgers, The State University of New Jersey
Phase 1 Terminated
NCT02303028 2022-06-28
TOPAZ
The Hospital for Sick Children
Phase 1/2 Completed
NCT02450136 2022-06-15
Single-arm Study to Evaluate the Safety and Efficacy of Pazopanib, in Subjects With FGFR2 Amplification, FGFR2 Mutation Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed
NCT02691767 2022-06-15
Study to Evaluate the Safety and Efficacy of Pazopanib, in Subject With Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed
NCT02354612 2021-02-15
Open Label Continuation Study of TRC105 for Patients Who Have Completed a Prior TRC105 Trial
Tracon Pharmaceuticals Inc.
No longer available
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT01713972 2019-03-01
Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT03628131 2018-09-19
Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors
Samsung Medical Center
Phase 1/2 Unknown
NCT00732420 2017-11-13
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT01485042 2017-09-01
PATH
Duke University
Phase 1 Completed
NCT01072890 2012-03-28
Temsirolimus and Pazopanib in Patients With Advanced Solid Tumors
University of California, Davis
Phase 1 Completed